Arcturus Therapeutics Holdings (ARCT)
(Real Time Quote from BATS)
$25.55 USD
+0.30 (1.19%)
Updated Oct 2, 2024 02:08 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for Arcturus Therapeutics Holdings Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 167 | 206 | 12 | 10 | 21 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 167 | 206 | 12 | 10 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 245 | 194 | 215 | 81 | 46 |
Income After Depreciation & Amortization | -78 | 12 | -203 | -72 | -26 |
Non-Operating Income | 34 | -1 | 1 | 0 | 0 |
Interest Expense | -17 | 0 | 2 | 0 | 0 |
Pretax Income | -28 | 11 | -204 | -72 | -26 |
Income Taxes | 2 | 1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | 9 | -204 | -72 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | 9 | -204 | -72 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | 14 | -202 | -71 | -25 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -78 | 12 | -203 | -72 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.63 | 27.09 | 26.32 | 20.31 | 12.07 |
Diluted EPS Before Non-Recurring Items | -1.99 | 0.35 | -7.74 | -3.55 | -2.15 |
Diluted Net EPS (GAAP) | -1.12 | 0.35 | -7.74 | -3.55 | -2.15 |
Fiscal Year end for Arcturus Therapeutics Holdings Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 49.86 | 38.01 | 30.86 | 45.14 | 10.52 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 49.86 | 38.01 | 30.86 | 45.14 | 10.52 |
SG&A, R&D, and Dept/Amort Expenses | 70.99 | 68.42 | 49.13 | 64.46 | 65.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | -21.13 | -30.41 | -18.27 | -19.32 | -55.38 |
Non-Operating Income | -0.39 | 4.02 | -0.05 | 0.00 | 0.15 |
Interest Expense | -4.15 | 0.05 | -6.88 | -3.98 | -3.25 |
Pretax Income | -17.37 | -26.45 | -11.45 | -15.33 | -51.97 |
Income Taxes | -0.15 | 0.37 | 0.26 | 0.89 | 0.58 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.22 | -26.82 | -11.71 | -16.22 | -52.55 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.22 | -26.82 | -11.71 | -16.22 | -52.55 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 26.97 | 26.88 | 26.63 | 26.57 | 26.56 |
Diluted EPS Before Non-Recurring Items | -0.64 | -1.00 | -0.32 | -0.61 | -1.98 |
Diluted Net EPS (GAAP) | -0.64 | -1.00 | -0.40 | -0.61 | -1.98 |